SynthesisBMC cancer2026
The effectiveness of gender-neutral HPV vaccination programmes in preventing HPV-associated oral cancers: a systematic review.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman papillomavirus infections are a significant risk factor for the development of oral cancers. While HPV vaccines have proven effective in preventing cervical cancers, their impact on oral cancers remains insufficiently examined. This systematic review assesses the effectiveness of gender-neutral HPV vaccination in reducing oral HPV rates, a key precursor to HPV-associated oral cancers, focusing exclusively on studies including gender-neutral samples.
methodsFollowing PRISMA 2020 guidelines, a comprehensive search strategy was implemented, covering multiple databases, including MEDLINE and Embase, as well as grey literature and ongoing trials sources via WHO ICTRP, EUCTR and ClinicalTrials.gov. Inclusion criteria encompassed studies published between 2009 and 2025 with gender-neutral samples, oral HPV prevalence data, and vaccination status information. Quality of the included studies was assessed using the JBI Critical Appraisal Checklists.
resultsNine observational studies were included, with sample sizes ranging from 394 to 9,437 participants and age ranges spanning from 18 to 70 years across multiple countries, including the United States, Australia, and Italy. Six studies reported lower prevalence of oral vaccine-type HPV (VT-HPV) among vaccinated individuals, with relative reductions ranging from 57.5% to 93.2% and an overall mean reduction of 78.5%. Lower prevalence was observed even after a single vaccine dose. In sex-stratified analyses, females showed a mean reduction of 86.8%, while males showed a mean reduction of 69.1%, with two studies reporting 100% protection among vaccinated males. Heterogeneity in outcome definitions, reporting formats, and sample overlap precluded meta-analysis.
conclusionsThis is the first systematic review focusing exclusively on gender-neutral samples. The findings suggest that gender-neutral HPV vaccination programmes, which are associated with lower oral prevalence of vaccine-type HPV, may contribute to reducing the burden of HPV-associated oral cancers. Including males in national immunisation strategies is essential to promote equity and maximize public health impact, particularly given the higher burden of HPV-associated oropharyngeal cancers in men. Further research is required to better understand this effect, including the influence of dose number and the potential role of sex in vaccine response. REGISTRATION: PROSPERO (CRD420251144148).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.